Homologous and Heterologous Covid-19 Booster Vaccinations.
Robert L AtmarKirsten E LykeMeagan E DemingLisa A JacksonAngela R BrancheHana M El SahlyChristina A RostadJudith M MartinChristine JohnstonRichard E RuppMark J MulliganRebecca C BradyRobert W FrenckMartín BäckerAngelica C KottkampTara M BabuKumaravel RajakumarSrilatha EdupugantiDavid DobrzynskiRhea N ColerChristine M PosavadJanet I ArcherSonja CrandonSeema U NayakDaniel SzydloJillian A ZemanekClara P Dominguez IslasElizabeth R BrownMehul S SutharM Juliana McElrathAdrian B McDermottSarah E O'ConnellDavid C MontefioriAmanda EatonKathleen M NeuzilDavid S StephensPaul C RobertsJohn H Beigelnull nullPublished in: The New England journal of medicine (2022)
Homologous and heterologous booster vaccines had an acceptable safety profile and were immunogenic in adults who had completed a primary Covid-19 vaccine regimen at least 12 weeks earlier. (Funded by the National Institute of Allergy and Infectious Diseases; DMID 21-0012 ClinicalTrials.gov number, NCT04889209.).